摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-2-(3,4-Dichlor-benzyliden)-acetessigsaeure-aethylester | 24393-32-6

中文名称
——
中文别名
——
英文名称
cis-2-(3,4-Dichlor-benzyliden)-acetessigsaeure-aethylester
英文别名
ethyl (2Z)-2-[(3,4-dichlorophenyl)methylidene]-3-oxobutanoate
cis-2-(3,4-Dichlor-benzyliden)-acetessigsaeure-aethylester化学式
CAS
24393-32-6
化学式
C13H12Cl2O3
mdl
——
分子量
287.142
InChiKey
IVTQTRHAXPKHOI-POHAHGRESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Method of treating proliferative diseases using Eg5 inhibitors
    申请人:——
    公开号:US20020165240A1
    公开(公告)日:2002-11-07
    The invention provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor. The invention also provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor in combination with at least one other anti-cancer agent.
    本发明提供了一种通过调节Eg5蛋白活性治疗疾病的方法,包括向需要此类治疗的哺乳动物物种中给予至少一种小分子Eg5蛋白抑制剂的有效量。本发明还提供了一种通过调节Eg5蛋白活性治疗疾病的方法,包括向需要此类治疗的哺乳动物物种中给予至少一种小分子Eg5蛋白抑制剂和至少一种其他抗癌剂的有效量。
  • EP1372657A4
    申请人:——
    公开号:EP1372657A4
    公开(公告)日:2005-11-09
  • A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP1372657A2
    公开(公告)日:2004-01-02
  • US4621082A
    申请人:——
    公开号:US4621082A
    公开(公告)日:1986-11-04
  • [EN] A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS<br/>[FR] TRAITEMENT DE MALADIES PROLIFERATIVES AU MOYEN D'INHIBITEURS DE EG5
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2002078639A2
    公开(公告)日:2002-10-10
    The invention provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor. The invention also provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor in combination with at least one other anti-cancer agent.
查看更多